Inve India ▾

Sun Pharmaceutical Industries share price & results

Sun Pharmaceutical Industries Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's largest drugmaker and 13th-largest US generics maker, selling specialty and generic drugs in 100+ countries

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue15,300 ₹ crore+10.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin29.0 %−2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit2,901 ₹ crore+26.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity16.22 %−0.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin15.23 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)11.41 %+2.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 9 judged targets kept · 9 open · verdicts reflect calls analysed to Q1 FY27.

Sun Pharmaceutical Industries Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (6 achieved, 3 missed, 9 open).

TargetOriginal wordingSaidLatest callVerdict
Leqselvi US Launchquarter two (Q2 FY26)
Call transcript, Q4 FY25 · 29 May 2025		Q4 FY25Q1 FY27:Post-launch progress confirmed: 'we added an important plan just this past quarter and improved the overall access.' Promise remains achieved.
Call transcript, Q1 FY27 · 31 Jul 2026		Achieved
Consolidated Topline Growthmid to high single digit
Call transcript, Q4 FY25 · 29 May 2025		Q4 FY25Q1 FY27:Final FY26 results were not provided, as the call focused on Q1 FY27 performance. The deadline has passed.
Call transcript, Q1 FY27 · 31 Jul 2026		Achieved
Synergy realization from Organon acquisition$350 million
Call transcript, Q1 FY27 · 31 Jul 2026		Q1 FY27Q1 FY27:Acquisition is on track to close by early 2027. No update on synergies as the deal is not yet closed.
Call transcript, Q1 FY27 · 31 Jul 2026		On Track

Source: Inve Guidance Tracker for Sun Pharmaceutical Industries Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Sun Pharmaceutical Industries Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,740 −0.46% · −₹8

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +2.4% 1Y

₹1.6k₹1.7k₹1.8k₹1.9k₹2.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 30 Jan 2026Q4 FY26 — 27 Apr 2026Q1 FY27 — 31 Jul 2026

1Y: ₹1,699 on 24 Oct 2025 → ₹1,740. High ₹2,001.1 (30 Jul 2026), low ₹1,589.3 (29 Jan 2026).

Previous close
₹1,748
Market cap
₹4.2L Cr
52-week range
₹1,589.3 – ₹2,001.1
One year
+2.74%
Price to earnings (TTM to Jun 2026)
33.37×
Return on equity (TTM to Jun 2026)
16.22%

Overview

Symbol
NSE:SUNPHARMA
Exchange
NSE
Currency
INR

What Sun Pharmaceutical Industries Limited does

Based on the company's own presentations, annual report and earnings calls.

Sun Pharmaceutical Industries is a global specialty and generic pharmaceutical company — the largest drugmaker in India and the 13th-largest generics company in the US. It develops, manufactures and markets branded generics, specialty (innovative) medicines, pure generics and active pharmaceutical ingredients (APIs), selling across more than 100 countries from 40 manufacturing facilities. Revenue is earned across several business lines spanning fast-growing Innovative Medicines, US Generics, India branded generics, Emerging Markets and Rest-of-World developed markets.

Segments

  • Innovative Medicines
  • US Generics
  • India
  • Emerging Markets
  • Rest of World
  • APIs
Market position in India
No.1 — largest pharma company in India, ranked No.1 by prescriptions across 14 prescriber categories
US generics ranking
13th largest generics company in the US
Countries of operation
100+ countries
Manufacturing facilities
40
India field force
15,000+ representatives
R&D headcount
2,900+ across several R&D centres
Founded 1993Headquarters Mumbai, Maharashtra, IndiaEmployees 43,000 (FY25) Company website

How the price took the results

close before → close after

Q1 FY27
−0.5%
31 Jul
Q4 FY26
+7.0%
27 Apr
Q3 FY26
+0.9%
31 Jan
Q2 FY26
+1.1%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sun Pharmaceutical Industries Limited

Free account: one company. Everything above stays public.

Write why you follow Sun Pharmaceutical Industries Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sun Pharmaceutical Industries Limited

Guides on how to read this kind of business and the numbers that matter.